Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
138 studies found for:    Open Studies | "Nasopharyngeal Neoplasms"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Nasopharyngeal Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Trial of Endostar in Patients With Carcinoma of the Head and Neck
Condition: Nasopharyngeal Neoplasms
Intervention: Drug: Endostar
2 Not yet recruiting ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Condition: Nasopharyngeal Neoplasms
Interventions: Drug: Apatinib;   Drug: Placebo
3 Not yet recruiting Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
Conditions: Nasopharyngeal Neoplasms;   Stomatitis
Interventions: Drug: Oral Ulcer Gargle (FORRAD®);   Drug: Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine
4 Not yet recruiting Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
Conditions: Nasopharyngeal Neoplasms;   Radiodermatitis
Interventions: Drug: Medical Radiation Protectants (FORRAD®);   Drug: Trolamine (Biafine)
5 Recruiting Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Interventions: Radiation: IMRT using individualized CTV;   Radiation: IMRT using traditional CTV;   Drug: Gemcitabine and cisplatin (induction chemotherapy);   Drug: Docetaxel and cisplatin (induction chemotherapy);   Drug: Cisplatin 100mg/m² concurrent chemotherapy;   Drug: Cisplatin 80mg/m² concurrent chemotherapy
6 Recruiting Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)
Condition: Nasopharyngeal Neoplasms
Interventions: Biological: Pembrolizumab;   Drug: Capecitabine;   Drug: Gemcitabine;   Drug: Docetaxel
7 Recruiting Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.
Conditions: Nasopharyngeal Neoplasms;   Mortality;   Quality of Life;   Complications
Interventions: Radiation: Hyperfractionated IMRT;   Radiation: Conventional Fraction IMRT
8 Recruiting Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Carboplatin
9 Recruiting Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Neoplasms;   Blood Cell Count;   Neoplasm Staging;   Prognosis
Intervention:
10 Recruiting A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
Conditions: Nasopharyngeal Neoplasms;   Salivary Gland Diseases;   Bone Marrow Diseases;   Mucositis
Interventions: Drug: Amifostine every-other-day regimen;   Drug: Amifostine everyday regimen
11 Unknown  Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer
Condition: Nasopharyngeal Neoplasms
Interventions: Procedure: Conventional Radiotherapy;   Procedure: Accelerated Radiotherapy;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Capecitabine
12 Unknown  Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Neoplasms
Intervention: Drug: Oxaliplatin
13 Recruiting EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
Conditions: Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M);   Breast Cancer Recurrent
Intervention: Biological: CAR-T cells recognizing EpCAM
14 Not yet recruiting The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma
Condition: Effects of Chemotherapy
Interventions: Drug: Concurrent chemotherapy with cisplatin;   Radiation: Intensity modulated radiotherapy
15 Not yet recruiting The Study to Evaluate JS001 in Patients With Advanced GC, ESCC, NPC, HNSCC
Conditions: Gastric Adenocarcinoma;   Esophageal Squamous Cell Carcinoma;   Nasopharyngeal Carcinoma;   Head and Neck Squamous Cell Carcinoma
Interventions: Biological: 3 mg/kg humanized anti-PD-1 mAb;   Biological: 10 mg/kg humanized anti-PD-1 mAb
16 Not yet recruiting Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Endostar;   Drug: DDP
17 Recruiting A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
Condition: Nasopharyngeal Carcinoma.
Intervention: Drug: S-1
18 Not yet recruiting Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
Condition: Nasopharyngeal Cancer
Intervention: Drug: Avelumab
19 Not yet recruiting Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Cisplatin combine with IMRT
20 Not yet recruiting Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients
Condition: Nasopharyngeal Carcinoma
Interventions: Dietary Supplement: Sodium nitrate;   Dietary Supplement: sodium chloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years